Encouraging long-term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for high-risk patients with resectable pancreatic carcinoma.

MLA

AlMasri, Samer S., et al. “Encouraging Long-Term Survival Following Autophagy Inhibition Using Neoadjuvant Hydroxychloroquine and Gemcitabine for High-Risk Patients with Resectable Pancreatic Carcinoma.” Cancer Medicine, vol. 10, no. 20, Oct. 2021, pp. 7233–41. EBSCOhost, https://doi.org/10.1002/cam4.4211.

APA

AlMasri, S. S., Zenati, M. S., Desilva, A., Nassour, I., Boone, B. A., Singhi, A. D., Bartlett, D. L., Liotta, L. A., Espina, V., Loughran, P., Lotze, M. T., Paniccia, A., Zeh, H. J., 3rd, Zureikat, A. H., & Bahary, N. (2021). Encouraging long-term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for high-risk patients with resectable pancreatic carcinoma. Cancer Medicine, 10(20), 7233–7241. https://doi.org/10.1002/cam4.4211

Chicago

AlMasri, Samer S, Mazen S Zenati, Annissa Desilva, Ibrahim Nassour, Brian A Boone, Aatur D Singhi, David L Bartlett, et al. 2021. “Encouraging Long-Term Survival Following Autophagy Inhibition Using Neoadjuvant Hydroxychloroquine and Gemcitabine for High-Risk Patients with Resectable Pancreatic Carcinoma.” Cancer Medicine 10 (20): 7233–41. doi:10.1002/cam4.4211.